Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.59 |
| ▸ | CXCR4 | P61073 | 7/20 | 0.58 |
| ▸ | BDKRB2 | P30411 | 5/20 | 0.57 |
| ▸ | CXCL8 | P10145 | 5/20 | 0.56 |
| ▸ | TACR1 | P25103 | 1/20 | 0.54 |
| ▸ | MC4R | P32245 | 1/20 | 0.53 |
| ▸ | MC5R | P33032 | 1/20 | 0.53 |
| ▸ | MC3R | P41968 | 1/20 | 0.53 |
| ▸ | MC1R | Q01726 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30526207 | 1.00 | C5AR1 (0.59) | C5AR1CXCR4BDKRB2CXCL8TACR1 | |
| SCHEMBL30526208 | 1.00 | C5AR1 (0.59) | C5AR1CXCR4BDKRB2CXCL8TACR1 | |
| SCHEMBL30526206 | 1.00 | C5AR1 (0.59) | C5AR1CXCR4BDKRB2CXCL8TACR1 | |
| SCHEMBL30526210 | 1.00 | C5AR1 (0.59) | C5AR1CXCR4BDKRB2CXCL8TACR1 | |
| SCHEMBL30526212 | 1.00 | C5AR1 (0.59) | C5AR1CXCR4BDKRB2CXCL8TACR1 | |
| SCHEMBL30526202 | 1.00 | C5AR1 (0.59) | C5AR1CXCR4BDKRB2CXCL8TACR1 | |
| SCHEMBL30526205 | 1.00 | C5AR1 (0.59) | C5AR1CXCR4BDKRB2CXCL8TACR1 | |
| SCHEMBL30526204 | 1.00 | C5AR1 (0.59) | C5AR1CXCR4BDKRB2CXCL8TACR1 | |
| SCHEMBL30526213 | 1.00 | C5AR1 (0.59) | C5AR1CXCR4BDKRB2CXCL8TACR1 | |
| SCHEMBL29973237 | 0.91 | BDKRB2 (0.64) | BDKRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11723945-B2 | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions | TEMPLE OTORONGO LLC (US) | 2023-08-15 | — | — | US | claimed |
| US-20260144842-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS | TEMPLE OTORONGO LLC (US) | 2026-05-28 | — | — | US | disclosed |
| US-11723945-B2 | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions | TEMPLE OTORONGO LLC (US) | 2023-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144842-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS | OPRK1, TPH1, HTR3C | C5AR1 2612/4885CXCR4 2640/4885BDKRB2 102/4885 |
| US-11723945-B2 | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions | TPH1, TPH2, SYMPK | C5AR1 3121/4885CXCR4 1643/4885BDKRB2 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.